The search for an alternative to opioid drugs for pain relief has dragged one for decades, with little success, but Vertex Pharma thinks that could be about to change.
SMi Group reports: Key high profile industry experts to speak at 20th Annual Pain Therapeutics Conference on 11th and 12 May – Virtual Conference – Online Access Only.
SMi Group have released an official chair invite letter from Kerrie Brady, Chief Business Officer, Centrexion Therapeutics and Michael Scherz, Founder & CEO, Metys Pharma for Pain Therapeutics
The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia.
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio